P-0175 Current Treatment Patterns in 1st (1L) and 2nd Line (2L) Treatment for Metastatic Colorectal Cancer (MCRC) in Western Europe

Introduction Treatment patterns for mCRC vary across countries in Western Europe, which may influence patient outcomes. This study describes the latest use of chemotherapy regimens and monoclonal antibodies (mabs) in clinical practice in 1L and 2L across five countries. Methods Using physician survey data from Oncology Analyzer databaseTM in five European countries (Germany, Spain, Italy, France and United Kingdom (UK)), treatment patterns for 1L and 2L mCRC patients were assessed. Patients≥21 years with mCRC, treated between January 2009 and December 2010 undergoing chemotherapy and who were not in clinical trials were included. Results 4919 stage IV patients were identified in 1L and 2L (3937 and 982, respectively). Overall, median age category in 1L was 66-70yrs (59.2% male) and 61-65yrs in 2L (63.6% male). With regards to metastases, approximately 75% of patients had liver metastases and 35% had lung metastases. In 1L, patients in Germany, UK and Spain were more commonly administered an oxaliplatin containing regimen (47.8%, 58.7% and 47.5%, respectively), while in 2L, patients were more commonly administered an irinotecan containing regimen (55.3%, 50.8% and 46.2%, respectively). In France and Italy, the use of an irinotecan containing regimen was more common than an oxaliplatin containing regimen (France 1L: 46.5% vs. 34.7%, 2L: 49.3% vs. 26.5% and Italy 1L: 43.7% vs. 41.9%, 2L: 53.1% vs. 26.8%). The top 3 regimens are shown in the table by country: Conclusion Standard of care across Western EU for mCRC includes oxaliplatin and irinotecan containing chemotherapy regimens routinely combined with mabs. The preferred treatment regimens are different amongst the five European countries studied. In the UK, treatment with mabs is uncommon and capecitabine containing regimens are routinely used, which is consistent with NICE recommendations. Further research should be done to ascertain impact on patient outcomes for variation in treatment patterns across EU countries. Table 1 .